Friday, November 13, 2026
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Earnings callNasdaq· November 27, 2025

EPR Properties EPR Q3 2025 Earnings Transcript

View original at nasdaq.com
“Liquidity Position -- $13.7 million cash on hand, $379 million drawn on $1 billion revolver.”
Verbatim excerpt from the source · Nasdaq · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • EPR's investment pipeline is actionable over the next 90-120 days with over $100M in committed unfunded projects

    80% confidence
  • If Genting transaction executes, it would delever EPR's balance sheet by approximately 0.3 turns

    80% confidence
  • EPR can reach target leverage without Genting proceeds or significant asset sales

    80% confidence
  • EPR has a 25-year track record navigating economic cycles and understands the importance and resilience of congregate value-oriented entertainment and leisure

    80% confidence
  • EPR projects 2026 investment spending acceleration in the $400M-$500M range

    80% confidence
  • Small bespoke relationship deals ($25M-$75M) are yielding comfortably in the 8s with less competition

    80% confidence
  • Full year 2025 box office is forecast at $9.0B-$9.2B, up approximately 6% at midpoint versus 2024

    80% confidence
  • Three Q4 2025 films (Zootopia 2, Wicked: For Good, Avatar: Fire & Ash) are each projected to exceed $200M in box office

    80% confidence
  • Genting intends to complete bond transaction and option exercise with EPR in 2026

    80% confidence
  • Percentage rent was $7M in Q3 2025 versus $5.9M in prior year, representing a key income growth driver

    80% confidence
  • The Genting transaction was never a requirement for EPR's 2026 growth plan

    80% confidence

Cited in these Via News reports

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Late-2026 Biotech Catalyst Season: FDA Decisions and Pivotal Readouts Converge Across Oncology, Hepatology and Cardiometabolic
Mid-November 2026 is dense with scheduled biotech catalysts. The ivonescimab BLA PDUFA date is 2026-11-14, the lorundrostat PDUFA date is 2026-12-22, and Phase 3 ECLIPSE hepatitis delta data are due in Q1 2027. Alongside these, siRNA and antibody programs (plozasiran, elebsiran/tobevibart, ianalumab, nipocalimab) reported or presented data at AHA, AASLD, ACR and ASH, while Oryzon advanced iadademstat in AML with Spanish trial authorizations and a planned ALICE-3 Phase III. Late-stage data and regulatory milestones are driving the sentiment. A planned delisting (EGM 2026-11-19, application 2027-01-25) is a separate corporate-structure event with no clear link to the rest.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,577 source documents archived
Query this data → isubstrate.com